MedTrace Logo

A Study To Evaluate The Effect Of WELLBUTRIN XL On Intraocular Pressure

NCT00439868 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2017-08-10

No results posted yet for this study

Summary

This study will be conducted in healthy volunteers to investigate the effect on intraocular pressure of 2 weeks of treatment with 300mg WELLBUTRIN XL/day.

Conditions

  • Depressive Disorder

Interventions

DRUG

WellbutrinXL

WELLBUTRIN XL tablets will be available with dose strength of 150 and 300 mg.

DRUG

placebo

Matching placebo tablets to WELLBUTRIN XL.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-02-16
Primary Completion
2007-06-08
Completion
2007-06-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00439868 on ClinicalTrials.gov